Alphamab Wins CDE Nod for First-in-Class Dual-Payload Cancer ADC JSKN021

Alphamab Oncology ( (HK:9966) ) has provided an announcement.

Alphamab Oncology has had its Investigational New Drug application for JSKN021, a first-in-class dual payload bispecific antibody-drug conjugate targeting EGFR and HER3, officially accepted by China’s Center for Drug Evaluation, paving the way for a phase I trial in advanced solid tumors. The study will assess safety, tolerability, pharmacokinetics and antitumor activity, supported by preclinical data showing superior tumor inhibition versus single-payload ADCs, underscoring the company’s strategy to leverage its ADC and protein engineering platforms to address resistance in cancer therapy and strengthen its position in the competitive oncology biologics market.

The most recent analyst rating on (HK:9966) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.

More about Alphamab Oncology

Alphamab Oncology is a leading biopharmaceutical company in China focused on antibody-based oncology therapies, underpinned by proprietary platforms in antibody-drug conjugates, bispecific antibodies and multi-functional protein engineering. Its in-house pipeline spans ADCs, monoclonal and bispecific antibodies at various clinical stages, including one NMPA-approved product and several candidates in phase III or pivotal trials, positioning it as an emerging innovator in targeted cancer treatments.

Average Trading Volume: 1,457,329

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.7B

See more insights into 9966 stock on TipRanks’ Stock Analysis page.